1. Executive Summary

Bricopia is building the first Biological Asset-Backed Security (BABS) infrastructure, a new category of real-world asset (RWA) that turns physically stored, FDA-grade cord blood stem cells into verifiable, on-chain financial assets.

Biological samples hold enormous medical and commercial value, yet the industry lacks the infrastructure to standardize, verify, finance, and audit them. As a result, billions of dollars of biological assets sit illiquid and underutilized. Bricopia closes this gap by combining a monopoly position in FDA-registered cell-banking automation with a blockchain registry and a two-layer token system: BRIC and BRICO.

The foundation of the platform is hardware. Through its subsidiary ThermoGenesis, also referred to as "TG Medical," Bricopia is the only FDA-registered automation-equipment supplier in cell banking, serving 130+ major institutions across 30+ countries, with more than 1.4 million automated cord blood unit (CBU) procedures performed. This automated processing, storage, and verification stack uniquely satisfies the three core requirements of a credible RWA: anti-counterfeiting, one-to-one asset mapping, and third-party auditability.

Key Metrics

Core Idea

Cord blood is a biological asset with stable intrinsic value: "cell gold." Each FDA-approved CBU is priced around US$50,000. By mapping each verified unit to tokens, with 1 BRIC = 100 BRICO and 1 BRICO ≈ US$1 in the primary market, Bricopia separates ownership from liquidity and unlocks value that was previously trapped in cold storage.

Beyond financial innovation, Bricopia is structured for social impact. A companion 501(c)(3) foundation is designed to provide subsidized insurance and fund cell-and-gene-therapy (CGT) research, so that the benefits of regenerative medicine become more broadly and fairly accessible.

At a Glance